Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2248761 + raltegravir
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK2248761 + raltegravir is a combination of two investigational and approved antiretroviral agents for the treatment of HIV infection. GSK2248761 is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by GSK. Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents the integration of HIV DNA into the host genome and is marketed under the brand name Isentress by Merck & Co. This combination has been studied for potential pharmacokinetic interactions and was found to have no clinically significant interaction when co-administered. Both drugs act on different stages of the HIV replication cycle—GSK2248761 inhibits reverse transcription while raltegravir blocks viral DNA integration—making them suitable for use in combination antiretroviral therapy[2][7].
- Brand names
- Isentress HD
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on GSK2248761 + raltegravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2248761 + raltegravir.